The Biotech Cash Paradox

Traditional financial theory states that the capital structure of a company should be independent of the value of the underlying assets of the company. Intuitively this makes sense in that the business doesn’t change if the company raises equity, convertible, or debt...

Fundraising in today’s choppy public markets

I went to a Wharton Healthcare Alumni event on Tuesday night in New York and listened to a very interesting panel on alternative financing for biotech companies. This wasn’t your “apply for a grant or get a partner” discussion, it revolved around...

Good articles on biotech finance

I know that for my first real blog entry I shouldn’t simply reference someone else’s work but rather write my own. Who said, however, that those were the rules. After searching a few VC websites for a friend, I found several articles written by folks at De...

Hello world!

Welcome to my new blog about biotech and finance! While I don’t know fully what topics I might discuss, I envision both stories, lessons, and general posts about biotech entrepreneurship, venture capital, business development, corporate finance, public biotech...